Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Endothelial progenitor cells predict metastatic disease in children with cancer: Study

Endothelial progenitor cells may play a role in the start and progression of metastatic disease in children with cancer, according to study results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Sep 2010

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Asuragen, Inc. announced today the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics.

23 Sep 2010

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.

23 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Masonic Cancer Center receives five-year program project research grants from NCI

Two of the University of Minnesota Masonic Cancer Center's leading physician-scientists on research and treatment of cancers of the blood and bone marrow Philip McGlave, M.D., and Jeffrey Miller, M.D., have received renewed five-year program project research grants totaling almost $26 million from the National Cancer Institute (NCI).

23 Sep 2010

G-CSF compound may activate virus, increases risk of infection: Research

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

22 Sep 2010

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Impact of cancer treatment on cardiovascular function

For the past two decades, cancer therapy has become more sophisticated and effective, resulting in an ever-expanding group of long-term cancer survivors. There is also a growing awareness of the potentially negative effects of cancer treatment on the heart and the management of cardiac disease during and after cancer therapy.

22 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Cook Medical expands Spectrum Turbo-Ject line of antibiotic impregnated PICCs for CRBSIs

Responding to increased demand for technology to help prevent potentially fatal catheter-related bloodstream infections (CRBSIs), Cook Medical has expanded its Spectrum Turbo-Ject line of antibiotic impregnated peripherally inserted central venous catheters (PICCs) to treat a wider range of patient needs. For the first time, the clinical benefits of minocycline and rifampin-impregnated PICCs, a critical component in eliminating 250,000 potentially fatal CRBSIs in the U.S. annually, are now available in 3 French single and 6 French triple lumen sizes.

21 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Fat-derived stem cells can aid breast reconstruction after mastectomy

Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers at the University of Pittsburgh School of Medicine.

17 Sep 2010

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

A discovery made by Dr. Tarik Möröy, President and Scientific Director and Director of the IRCM, and his team was recently published in Blood, the official journal of the American Society of Hematology. The researchers found that a protein can regulate certain characteristics of blood stem cells, which could lead to a better treatment for leukemia patients.

17 Sep 2010

Bone Marrow News and Research

Further Reading

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Endothelial progenitor cells predict metastatic disease in children with cancer: Study

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Athersys presents MultiStem phase I study results at TCT Conference

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Masonic Cancer Center receives five-year program project research grants from NCI

G-CSF compound may activate virus, increases risk of infection: Research

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Impact of cancer treatment on cardiovascular function

FDA grants orphan drug designation for MultiStem stem cell therapy

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cook Medical expands Spectrum Turbo-Ject line of antibiotic impregnated PICCs for CRBSIs

Micromet initiates MT103 phase 2 trial in adult ALL patients

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Fat-derived stem cells can aid breast reconstruction after mastectomy

Scientists discover protein to regulate blood stem cells’ activity for leukemia treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News